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Abstract
Increased expression of cytokines and chemokines in the central nervous system
(CNS) is closely associated with the development of retroviral-induced neurological
diseases such as HIV-associated dementia, as well as other neuropathologies such as
Alzheimer’s Disease and Multiple Sclerosis. The specific functions of many of these
pro-inflammatory factors have yet to be elucidated in the disease process, and it is
unclear whether the nature of their effects is protective, pathogenic, or both.
Additionally, current models of chemokine function have inherent limitations, with direct
injection resulting in a brief response that doesn’t accurately represent the effects of
chronic production, and transgenic mice constitutively expressing chemokines by a large
percentage of intrinsic brain cells from inception. This study takes the first step in
developing a more representative in vivo system by which the direct of effects of the
over-expression of individual CNS chemokines may be studied. C17.2 neural stem cells
(NSC) were transduced with retroviral vectors containing the genes for CCL2, CCL7,
CCL12, or the vector alone, and were inoculated into mice to generate a more accurate
representation of the limited chemokine producing cell population that is seen with
disease. The in vivo data generated herein suggests that this system is capable of
consistently expressing comparable levels of these three chemokines, and characterizes
the migration patterns of these cells into the major regions of the CNS. As no significant
glial activation was seen concurrent with CCL over-expression, this study provides
support for idea that the CCL chemokines may be involved in priming the CNS immune
response, rather than its direct initiation. Additionally, ancillary histopathological data
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suggests a possible role for CCL12 in the development of spongiform lesions in the
presence of recombinant retrovirus infection.
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Introduction
The up-regulation of central nervous system (CNS) cytokines and chemokines is
closely associated with retrovirus-induced neurological diseases. For example, the
development of HIV dementia, SIV encephalitis, and murine retrovirus-induced
neurological disease correlate with increased expression of TNFα, CXCL10 (IP-10),
CCL3 (MIP-1α), CCL4 (MIP-1β), CCL5 (RANTES), CCL2 (MCP-1), CCL7 (MCP-3),
and CCL12 (MCP-5). However, the roles of these cytokines and chemokines in CNS
disease have yet to be clearly elucidated. Studies involving the neurovirulent murine
retrovirus Fr98 and chemokine receptor-deficient mice have suggested that CCL2, CCL7,
and/or CCL12 may contribute to retroviral pathogenesis, but presently an in vivo system
that accurately replicates the temporal, spatial, and quantitative expression of chemokines
in the CNS during neurological disease does not exist. This project attempts to take the
first step in developing a system useful for accurately studying the effects of a single
over-expressed chemokine in the CNS, and to overcome the limitations of previous
models that employed the use of transgenic mice and direct injection. Additionally, we
attempt to characterize the effect of CCL2, CCL7, and CCL12 over-expression to
determine the potential role of these genes in neuropathogenesis, and the activation of the
immune response in the brain.
The actions of these chemokines in the CNS were investigated by over-expression
of each gene of interest in the brain using C17.2 murine neural stem cells (NSCs) as
delivery vectors. In short, these NSCs were transduced using a pSFF retroviral vector
carrying the chemokine gene of interest, and then introduced into the CNS of neonatal
IRW mice by way of intracranial inoculation via the lateral ventricles. The mice were
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observed for any signs of clinical neurological disease until the brains were harvested at
7, 14, and 21 days post-inoculation. Histological analysis was performed on the tissues
to assess NSC distribution, detection of inflammatory infiltration, activation of astrocytes
and microglia, and the correlation of these pathologies with the localized expression of
chemokines from the NSCs using in situ hybridization and immunohistochemical dual
staining techniques. Molecular changes were quantified by real-time PCR mRNA
analysis to confirm and characterize expression levels of CCL2, CCL7, and CCL12, and
to check for up-regulation of astrocyte and microglia/macrophage activation markers.
As these chemokines have different effects on the peripheral immune response,
we hypothesized that their individual over-expression in the CNS would have differing
effects on the activation of microglia/macrophages and astrocytes, and the recruitment of
inflammatory macrophages and T lymphocytes. The specific aims of this project are to
characterize the use of retrovirally transduced C17.2 neural stem cells as an in vivo
delivery vector for CNS chemokine study, and to examine the immunopathological
response to over-expression of CCL2, CCL7, and CCL12.
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Review of Literature
Innate Immune Response and Neurological Disease
Though the specific causes of numerous instances of neurological dysfunction
have yet to be elucidated, extensive evidence has shown that clinical neurological disease
is consistently correlated with an up-regulation of CNS pro-inflammatory cytokines and
chemokines, as well as the activation of resident astrocytes and microglia/macrophages.
These findings are evident in both viral and non-viral mediated pathologies such as
Multiple Sclerosis (MS), Alzheimer’s Disease (AD), ischemia, Experimental
Autoimmune Encephalitis (EAE), Simian Immunodeficiency Virus (SIV), MuLVassociated disease, and HIV-associated dementia (HAD) (Conant et al., 1998; Godiska et
al., 1995; Karpus and Ransohoff, 1998; Luster, 1998; Orandle et al., 2002; Persidsky et
al., 1999; Schmidtmayerova et al., 1996; Van, V et al., 1999). In AD, while
inflammatory infiltration in the CNS has not been clearly demonstrated, activated
astrocytes and microglia/macrophages are typically associated with plaques, as are
increased levels of CCL2, CXCL10, and CCL4 (Akiyama et al., 2000; Ishizuka et al.,
1997; Xia et al., 2000; Xia et al., 1998). These observations are also seen in MS, along
with increased levels of CCL5 and CCL3 in chronic active lesions (Boven et al., 2000).
The presence of CCL2 and CCL7 has also been described in acute and chronic active MS
lesions, as well as in cerebral ischemia (Banisor et al., 2005; Chen et al., 2001; McManus
et al., 1998; Simpson et al., 1998). In EAE, which is a model for MS, increased levels of
CCL2, CXCL10, CCL5, and CCL7 have also been reported (Berman et al., 1996;
Godiska et al., 1995). Studies with EAE have demonstrated that antibodies against CCL2
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and CCL3 inhibit disease, which clearly indicates a role for cytokines and chemokines in
neuropathogenesis (Karpus and Kennedy, 1997).
In instances of SIV, MuLV, and HIV infections of the CNS there tend to be
conflicting reports as to the genesis of neurological dysfunction. While in some cases
there is significant CNS inflammatory infiltration and neuronal apoptosis, these
pathologies can not be consistently correlated to all incidences of neurological disease
(Adamson et al., 1996; Glass et al., 1995; Kaul and Lipton, 1999; Marcondes et al., 2001;
Persidsky et al., 1999; Portis et al., 1995). These viruses all infect similar cell types in
the CNS, including microglia/macrophages, and are closely associated with astrocyte and
microglia/macrophage activation (Adamson et al., 1996; Garden, 2002; Persidsky et al.,
1999; Peterson et al., 2004; Portis et al., 1995). Likewise, in all cases, the host response
to CNS infection includes significant cytokine and chemokine up-regulation, which
would seem to indicate some involvement in the development of clinical disease. The
observed increases in cytokine and chemokine levels are typically attributed to the
activated astrocytes and microglia/macrophages (Garden, 2002; Orandle et al., 2002;
Peterson et al., 2004). In SIV, encephalitic animals show elevated levels of TNFα, IL-1β,
CXCL10, CCL2, CCL7 (Orandle et al., 2002; Sasseville et al., 1996; Sopper et al., 1996).
In MuLV-infected mice there is significant up-regulation of TNFα, TNFβ, IL-1α, CCL2,
CCL3, CCL4, CCL5, CCL7, CCL12, CXCL1, and CXCL10 (Peterson et al., 2001;
Peterson et al., 2004). TNFα, TGFβ, IL-6, IL-1β, CXCL10, CCL2, CCL3, CCL4, and
CCL5 are also expressed at high levels in the CNS of HAD patients (Cinque et al., 1998;
Conant et al., 1998; Letendre et al., 1999; Perrella et al., 1992; Poluektova et al., 2001;
Wahl et al., 1991; Wesselingh et al., 1993). These observations clearly suggest some
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essential involvement of pro-inflammatory cytokines and chemokines in neurological
disease, whether in a neuroprotective role, which has been suggested, or as mediators of
pathogenesis.
Fr98-Mediated Neurological Disease
Neuropathogenesis induced by the murine retrovirus Fr98 correlates strongly with
the increased production of pro-inflammatory cytokines and chemokines, providing a
useful model to study the contribution of these immune factors to the disease process. In
this model Fr98 infection of neonatal mice leads to severe clinical disease characterized
by ataxia, seizures, and death, typically by days 14 to 16 post-infection, in nearly one
hundred percent of cases. In contrast, CNS infection of a closely related murine
retrovirus, Fr54, does not induce neurological disease (Peterson et al., 2001; Portis et al.,
1995). The primary difference between Fr98 and Fr54 is in the envelope protein,
indicating its important role in mediating pathogenesis. There are no differences,
however, between the two viruses with regard to the types of cells infected, or the
histopathology observed (Peterson et al., 2001). Both viruses primarily infect CNS
microglia/macrophages and endothelial cells, and occasionally oligodendrocytes. The
minimal pathology seen consists of astrogliosis and microgliosis, with some vacuolar and
neuronal degeneration (Peterson et al., 2001; Portis et al., 1995; Robertson et al., 1997).
Interestingly, similar levels of apoptosis gene expression are seen in both types of
infection, and no inflammatory infiltrate is associated with either virus (Peterson et al.,
2001). However, Fr98 infection differs from that of Fr54 with respect to increased viral
load, and activation of astrocytes and microglia/macrophages. Fr98 infection also
induces significant up-regulation of pro-inflammatory cytokines and chemokines in the
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brain, including TNFα, TNFβ, IL-1α, CCL2, CCL3, CCL4, CCL5, CCL7, CCL12, MIP2, and CXCL10, which is not observed in Fr54 infection (Peterson et al., 2001; Peterson
et al., 2004). This demonstrates that the up-regulation is not due to generic host response
to retroviral infection. It is important to note that the increased levels of cytokines and
chemokines seen in Fr98 infection occur prior to the increases in viral load and onset of
disease (Peterson et al., 2001). Additionally, decreased incidence of disease has been
observed in CCL2 antibody blocking experiments using the Fr98 model (Peterson et al.,
2004). In accordance with this observation, CCR2-/- mice infected with Fr98 have also
shown a decreased incidence of disease, further suggesting the involvement of its ligands,
CCL2, CCL7, and CCL12 in immune-mediated retroviral neuropathogenesis (Peterson et
al., 2004).
CCL2/MCP-1
CCL2 is a member of the β-chemokine subfamily which is classified by four
conserved cysteine residues, the first two of which are adjacent (Bacon et al., 2002;
Leonard and Yoshimura, 1990; Yoshimura et al., 1989). By far the most well
characterized member of this subfamily, the actions of CCL2 are still not completely
understood, as it seems to function in differing roles dependant upon the situation at
hand. The main receptor for this protein is CCR2, but it is also known to bind CCR4, as
well as the DARC and D6 chemokine receptors (Murphy, 2000; Peterson et al., 2004;
Ransohoff and Tani, 1998). Upon stimulation by CCL2, CCR2 and CCR4, as is typical
of G-protein-coupled receptors, cause a transient rise in cytosolic calcium levels (Bacon
et al., 2002; Murphy, 2000; Ransohoff and Tani, 1998). CCL2 has been shown to
stimulate and chemoattract monocytes, macrophages and microglia, as well as T cells,
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mast cells, dendritic cells, basophils, and NK cells (Allavena et al., 1994; Carr et al.,
1994; Eugenin and Berman, 2003; Fuentes et al., 1995; Gunn et al., 1997; Huang et al.,
2002; Taub et al., 1995). It is also known to stimulate and direct the migration of
astrocytes, and is a strong histamine-releasing factor for basophils (Andjelkovic et al.,
2002; Bischoff et al., 1992). CCL2 can be expressed by fibroblasts and monocytes, and
is induced in endothelial cells by IL-1β, IL-4, TNFα, and IFNγ (Rollins et al., 1990;
Rollins and Pober, 1991). It is also produced by microglia and astrocytes, the main
sources of CCL2 in the CNS, in response to stimulation by TNFα, IFNγ, IL-1β, TGFβ,
CCL3, CCL4, and CCL5 (Hurwitz et al., 1995; Legoux et al., 1992; McManus et al.,
2000; Peterson et al., 2004; Valente et al., 1998; Zhou et al., 1998). Concordantly, CCL2
also affects the production of other cytokines, enhancing the secretion of IL-4, IL-5, and
IL-10, while antagonizing the secretion of IL-12, and TNFα (Chensue et al., 1996; Gu et
al., 2000; Karpus et al., 1997; Matsukawa et al., 2000; Zisman et al., 1997).
Though its specific effects are not always obvious, the correlation between CCL2
and neurological disease has been well documented. It is a mediator of CNS
inflammation in a number of conditions, including EAE, MS, Alzheimer’s, ischemia, and
trauma (Berman et al., 1996; Che et al., 2001; Glabinski et al., 1996; Glabinski et al.,
1995; Gourmala et al., 1997; Grzybicki et al., 1998; McManus et al., 1998; Sun et al.,
2003; Van, V et al., 1999; Wang et al., 1995). However, transgenic mice with CNSspecific CCL2 expression showed little evidence of inflammation until stimulated with
pertussis toxin, an observation that suggests that it may prime the CNS for infiltration,
rather than directly recruiting inflammatory cells (Huang et al., 2002). With regard to
virally induced CNS disease, HAD patients have demonstrated substantial increases in
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CCL2 levels in brain tissue and cerebrospinal fluid, and polymorphism studies have
indicated that a certain allelic variant may increase susceptibility to the disease (Conant et
al., 1998; Gonzalez et al., 2002). However, while high CCL2 levels strongly correlate
with HAD, it is not clear whether its effects are damaging or protective. HIV tat protein
can induce the increased production of CCL2, and studies have shown that when added to
astrocyte and neuronal cultures simultaneously with tat, CCL2 inhibited apoptosis.
However, when added to the cultures after tat exposure it offered no protection (Conant
et al., 1998; Eugenin et al., 2003; Gonzalez et al., 2002; Lim and Garzino-Demo, 2000).
Several knockout studies have shown that CCR2-/- mice have a reduced incidence
of virally mediated clinical disease. This was observed with CNS infection of the Fr98
retrovirus, and also with mouse hepatitis virus (Chen et al., 2001; Peterson et al., 2004).
Since CCR2 is the main receptor for CCL2 in the CNS, these results suggest a pathogenic
role for this chemokine. Kinetic analysis of CCL2 expression during the course of Fr98
infection demonstrated an increase in production starting at day twelve post-infection,
prior to the development of clinical signs, with continued expression persisting
throughout the course of the disease (Peterson et al., 2004). Additionally, CCL2
antibodies administered to Fr98 infected mice were able to delay the onset of disease,
demonstrating further its potential role in virally induced CNS dysfunction (Peterson et
al., 2004).
CCL7/MCP-3
Originally identified from human osteosarcoma cells, the production of CCL7 in
peripheral blood mononuclear cells (PBMC) has been shown to be induced by
stimulation with IL-1β, IFNα, and IFNβ (Menten et al., 1999; Minty et al., 1993;
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Opdenakker et al., 1993; Van et al., 1992). While its function in disease processes has
not been well-defined, this member of the β-chemokine subfamily is an important
mediator of inflammation (Schols et al., 1997). Numerous studies have shown that this
protein is strongly chemotactic for monocytes and T lymphocytes, as well as eosinophils,
basophils, NK cells, and dendritic cells (Allavena et al., 1994; Dahinden et al., 1994;
Franci et al., 1995; Sozzani et al., 1994; Sozzani et al., 1995; Taub et al., 1995; Van et al.,
1992). Stimulation of these cells by CCL7 results in a rapid and transient concentrationdependent increase in cytosolic free calcium, inhibition of adenylyl cyclase, as well as the
release of histamine and leukotriene C4 (Dahinden et al., 1994; Franci et al., 1995). The
effects of CCL7 on monocyte chemotaxis and basophil mediator release are comparable
to CCL2, suggesting that the two chemokines utilize the same receptors and transduction
pathways (Dahinden et al., 1994; Franci et al., 1995). Accordingly, this does appear to be
the case, as CCL7 is now known to bind to CCR1, CCR2 (the main receptor for CCL2),
and CCR3 (Bacon et al., 2002; Bajetto et al., 2002; Franci et al., 1995; Murphy, 2000).
With respect to disease, CCL7 has demonstrated anti-tumor properties, as well as
anti-HIV activities against T-tropic viruses, most likely through competition with the
virus for cellular co-receptor binding (Hu et al., 2002; Schols et al., 1997). In instances
of neurological disease, its presence has been described in acute and chronic active MS
lesions, as well as in cerebral ischemia and mouse hepatitis virus-mediated disease (Lane
et al., 1998; McManus et al., 1998; Wang et al., 1999). Interestingly, there is also
evidence that CCL7 production is up-regulated at time points prior to immune cell entry
into inflammatory lesions in the CNS (Asensio and Campbell, 1997). This observation
also holds true with respect to Fr98-induced disease, where the levels of CCL7
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consistently rise several days before the appearance of clinical symptoms. However,
these increased levels are maintained only for a few days, and levels return to normal
around the time of the onset of disease (Peterson et al., 2004). While it is yet unclear
which CNS cells are responsible for the up-regulation of CCL7 in the Fr98 model, or
what its effect may be, the current data seems to suggest some role in the early phase of
the innate immune response to the infection.
CCL12/MCP-5
Murine CCL12 is a member of the β-chemokine subfamily, and there is currently
no known homologue in humans. Its roles in innate host defense and immune-mediated
pathogenesis have not been well-characterized, but some general information has been
elucidated. CCL12 is a product of activated macrophages and microglia, and its
production can be induced by IFNγ and LPS exposure (Peterson et al., 2004; Sarafi et al.,
1997). As with the other CCL chemokines, CCL12 is a mediator of inflammation. It is
strongly chemotactic for monocytes, and has also been shown to stimulate eosinophil
migration into the lungs (Gonzalo et al., 1998; Sarafi et al., 1997). It signals through
CCR2, and produces a rapid and transient rise in cytosolic calcium in cells which express
those receptors (Sarafi et al., 1997).
The only defined role for CCL12 in disease processes thus far is its involvement
in recruiting the early mononuclear phase of the inflammatory response (Sarafi et al.,
1997). This is evident in instances of inflammatory lesions in the CNS, where CCL12 is
up-regulated at time points prior to leukocyte entry (McTigue et al., 1998). In a model of
pulmonary nematode infection, CCL12 levels in the lungs were increased by day 7,
peaked at day 10, and had returned to baseline by day 14. In this instance the point of
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peak expression again preceded the peak recruitment of immune cells (Sarafi et al.,
1997). In the case of Fr98-mediated CNS disease, activated microglia appear to be the
likely source of the increased production of CCL12 (Peterson et al., 2004). Again, the
kinetic observations remain consistent, with CCL12 levels peaking and returning to
normal prior to the onset of disease. Interestingly, the increases in production becomes
evident a day or so earlier than the increases seen with CCL2 or CCL7 (Peterson et al.,
2004). This fact suggests the possibility of the involvement of CCL12 in the induction of
the other two CCL chemokines, as well as a general role in the induction of immunemediated neurological disease.
pSFF/C17.2 Murine Neural Stem Cell Chemokine Expression
The CNS chemokine over-expression in this project was accomplished using
pSFF vector-transduced C17.2 murine neural stem cells. pSFF is a retroviral expression
vector derived from the replication-defective spleen focus forming virus (SFFV). It has
been shown to be capable of high-level expression in murine stem cell lines in vitro
(Bestwick et al., 1988; Tumas et al., 1996). Following entry, the vector integrates stably
into the host cell genome and is thereafter transferred to the progeny of the transduced
cells (Tumas et al., 1996). In the construction of this vector the majority of the env gene
has been removed, and the space created is used to insert the gene of interest (Figure 1A)
(Tumas et al., 1996). To produce the retroviral particles carrying the gene of interest,
vector DNA is introduced into a mixed culture of the retroviral packaging cell lines ψ2
and PA317, each of which expresses a different retroviral env gene (Figure 1B)
(Bestwick et al., 1988). The ψ2 line releases ecotropic virions, while the PA317 line
releases amphotropic virions (Mann et al., 1983; Miller and Buttimore, 1986). Each cell
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Figure 1. pSFF vector (1A), and the pSFF/co-culture/C17.2 neural stem cell in vivo
chemokine expression system (1B). The pSFF plasmid DNA containing the CCL insert
is transfected into the ψ2/PA317 retroviral packaging cell co-culture. The ψ2 cells carry
an ecotropic retroviral envelope gene, and are susceptible to amphotropic viruses. The
PA317 cells carry an amphotropic retroviral envelope gene, and are susceptible to
ecotropic viruses. The co-culture of the two packaging cell lines results in high titers of
retroviral particles carrying the chemokine gene of interest. The co-culture supernatant is
then collected and used to transduce the C17.2 neural stem cell line. Once positive gene
expression is confirmed, the transduced C17.2 cells are inoculated into the CNS of
neonatal mice via the lateral ventricles.
12

line is resistant to superinfection by the type of virus that it releases, but is susceptible to
infection by the virions produced by the other cell type (Bestwick et al., 1988). The
result of this co-culture mechanism is a “ping-pong” effect that produces rapid and
efficient amplification of replication-deficient pSFF retroviral virions capable of infecting
different host ranges. The high-titer supernatant containing the amplified vector can be
collected and stored for later use (Bestwick et al., 1988).
C17.2 murine neural stem cells (NSCs) are a well-characterized line of stable,
self-renewing cellular clones, originally derived from neonatal mouse cerebellum (Ryder
et al., 1990). These NSCs are immature, multipotent cells found in both developing and
adult nervous systems that are capable of differentiating into most neuronal and
neuroglial lineages, and have been successfully used for in vivo gene expression in a
number of investigations(Lynch et al., 1999; Snyder et al., 1992). In culture they are
easily expanded and genetically manipulated, and when infected with pSFF vectors,
readily acquire the gene of interest (Bestwick et al., 1988; Lynch et al., 1999). After
confirmation of proper gene expression, the NSCs can be introduced directly into the
CNS of neonatal mice. The C17.2 cells are migratory post-inoculation, so wide
dissemination of the gene product is achieved. Owing to the introduction of the lacZ
reporter gene in the C17.2 line, β-galactosidase is stably expressed and in vivo
localization can be conveniently confirmed through immunohistochemistry (Snyder et al.,
1992).
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Rationale and Significance
The up-regulation of cytokines and chemokines in the CNS consistently correlates
with the incidence of neurological disease, as does the activation of astrocytes and
microglia. The chemokine CCL2 has been extensively studied in retrovirus-induced
neurological disease including HIV-associated dementia, and while evidence strongly
suggests it may have a role in mediating pathogenesis, that potential mechanism is not
known. CCL7 and CCL12 up-regulation is also associated with neurological disease, but
the functions of these chemokines have not been thoroughly examined, and it is not
known what role, if any, they may play in retroviral pathogenesis. However, the kinetics
of their expression in Fr98-induced disease suggests that they are in some way involved
in the disease process.
Previous studies using transgenic mice to express CCL2 in the CNS do not
accurately replicate chemokine expression in retrovirus-induced disease. In transgenic
mice, large populations of cells constitutively over-express CCL2 from inception, which
could result in tolerance and/or the development of compensatory pathways. In contrast,
the proposed model presents a novel approach for investigating the questions at hand.
With the use of C17.2 NSCs as an in vivo chemokine delivery system, more
representative levels and spatial dissemination of CNS chemokine expression can be
achieved. Thus, the major objectives of this project are to characterize the validity of the
C17.2 NSC gene expression system as an accurate in vivo model for chemokine
expression during neurological disease, and to determine whether or not increased levels
of CCL2, CCL7, or CCL12 in the CNS are involved in the activation of astrocytes and
microglia, or the general induction of neurological disease. Since CCL7 and CCL12
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have not been studied extensively, this undertaking will help to further characterize the
functions of these specific chemokines.
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Materials and Methods
CCL-pSFF Construct
The CCL2, CCL7, and CCL12 genes were cloned and ligated into the pSFF
retroviral plasmid by John Errett at Rocky Mountain Laboratories, NIAID, NIH. Briefly,
RNA isolates from the CNS of Fr98-infected mice were collected upon onset of clinical
disease. Samples were DNAse-treated and underwent reverse-transcriptase PCR to
generate cDNA templates. CCL2, CCL7, and CCL12 cDNA was then amplified for
cloning into the pSFF plasmid through PCR using the following primers:
CCL2-34f (with NheI site) TCATGCTAGCAGCACCAGCACCAGCCAAC
CCL2-539r (with Cla1 site) TCACATCGATAGGCATCACAGTCCGAGTC
CCL7-21f (with NheI site) CAAGCTAGCTGAAGCCAGCTCTCTCACTC
CCL7-348r (with ClaI site) GCCATCGATGGTTTCTGTTCAGGCACATTTC
CCL12-1f (with NheI site) TCGTGCTAGCTTCGAAGTCTTTGACCTCAAC
CCL12-366r (with ClaI site) TCACATCGATAATATCACACTGCCCGTGG
Amplicons were purified in Qiagen columns, and then ligated into TOPO pcrII. The
TOPO construct was then cut with EcoRI at either site of the insert and ligated into pSFF
plasmid also cut with EcoRI. Proper directional insertion was verified by restriction
digest and sequencing.
Cell Culture
Cell Maintenance. C17.2 murine neural stem cells were maintained in six well primaria
culture plates (Falcon, non-pyrogenic, surface modified polystyrene) in growth media
(DMEM high glucose with 1.5 g/L NaCO3, N2 Pyruvate, and 10% fetal bovine serum
(Hyclone characterized FBS)). Cells were passed at a 1:10 ratio upon producing a
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confluent monolayer on the bottom of the well. 1 ml of 0.25% trypsin was used to detach
cells in each well, and the proper dilution was then added to 3 ml fresh growth media.
The PA317 and ψ2 retroviral packaging cell lines were maintained and passed under
identical conditions and procedures, with the exceptions that the growth media used for
these cells was RPMI+NaHCO3 with 10% FBS, and the cells were grown in nonprimaria six well plates (Greiner Bio-one, Cellstar, non-pyrogenic, TC-plate). All cell
lines were grown in an incubator at 37º Celsius with 5% CO2.
Transfection. To produce the pSFF retroviral vectors containing the genes of interest,
co-cultures of PA317 and ψ2 cell lines were first established by plating aliquots of 2.5 x
10^5 of each line to the same well. After 24 hours the cells were removed from
incubation and transfected using Lipofectamine (Invitrogen) and the accompanying
protocol. Briefly, plasmid DNA was diluted in serum-free cell culture media, as was
Lipofectamine reagent. After a 5 minute incubation the diluted DNA and the diluted
reagent were combined so that a DNA/Lipofectamine ratio of 1µg/3µl was achieved.
After gently mixing, the solution was allowed to incubate for 20 minutes at room
temperature (RT). Aliquots of the transfection mixture were then added to each of the
wells containing the C17.2 cells with growth media. The plates were mixed by gentle
rocking and then placed back in the incubator for a minimum of 24 hours before testing
for transgene expression. To ensure successful transfection, the co-cultured cells were
immunofluorescently stained using the protocol listed below, and examined under a
fluorescent microscope for positive results. The antibody used was the monoclonal 34,
which is an anti-retroviral gag antibody (Chesebro et al., 1981). Once positive results
were obtained, the co-cultures were grown up in 175 cm² flasks (Greiner Bio-one,
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Cellstar, non-pyrogenic, filter cap) with 35 ml of RPMI growth media in order to collect
and store aliquots of the vectors. When cells were at roughly 75% confluency the growth
media was removed and a fresh 10 ml supply was added, and the cells were allowed to
grow for another 24 hrs. At that time the growth media was then collected and
centrifuged for five minutes at 1500 RPM in order to remove any cellular debris. The
supernatant was then divided into individual aliquots of 1 ml apiece and stored at -80º
Celsius.
Transduction. C17.2 cells were transduced using the previously collected pSFF
retroviral vectors virions containing the genes of interest (CCL2, CCL7, or CCL12), or
with the empty vector itself as a control. First, 2.5 x 10^5 cells were plated out in
multiple wells of a six well primaria plate. After 24 hours the cells were removed from
the incubator and the growth media was removed. 1 ml of DEAE-dextran/DMEM
growth media at a concentration of 8 µg/ml was added to each well of the plate, and
allowed to incubate at 37º C for 45 minutes. The DEAE-dextran/DMEM growth media
mixture was then removed, and an aliquot of pSFF vector virions was thawed, added to
each well, and allowed to incubate at 37º C for 1.5 hrs. After that time fresh DMEM
growth media was added, and the cells were maintained as previously described.
Immunofluorescent Staining/Flow Cytometry
For the purposes of flow cytometry all variations of the C17.2 cell line (including
all transduced lines) were grown up in 175 cm² flasks (Greiner Bio-one, Cellstar, nonpyrogenic, filter cap) with 35 ml of DMEM growth media. Initially split at a 1:3 ratio,
the cells were allowed to grow to confluency for 48 hrs before being harvested. To
collect the cells, the growth media was removed and 2 ml of 0.25% trypsin was used to
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wash the monolayer. 10 ml of 0.25% trypsin was then added to detach the cells into
solution. The trypsin/cell mixture was then added to 15 ml of DMEM growth media in
order to deactivate the trypsin. This mixture was then centrifuged for 5 minutes at 1500
RPM, and the supernatant discarded. The remaining pellet was dislodged, mixed, and
centrifuged in 10 ml of 1X Phosphate-Buffered Saline (PBS) in order to wash away any
remaining growth media. The supernatant was discarded, and the cells were brought up
in 1 ml of 1X PBS and distributed equally into individual wells of a 96-well round
bottom plate (Corning, costar, non-pyrogenic polystyrene) for staining. The plate was
centrifuged as before to form a pellet of cells on the bottom of each well, and the PBS
was discarded. Each well of cells was then brought up in 30 µl of FBS and allowed to
incubate at room temperature (RT) for 10 minutes to establish protein/protein interactions
and minimize cell loss during the staining process. After centrifugation and removal of
the FBS, the cells were washed with 100 µl of 1X PBS, centrifuged as before, and
allowed to incubate for 10 minutes at RT in 100 µl of 3.7% neutral buffered formalin for
fixation. Each well was washed twice with 1X PBS as before, brought up in 0.1%
saponin/1X PBS , and incubated for 20 minutes at RT in order to perforate the cell
membrane. Following centrifugation and removal of the saponin, 50 µl aliquots of each
primary antibody diluted in saponin (with the exception of the monoclonal antibodies
which were diluted in culture media) were added to the appropriate wells and allowed to
incubate for 1 hour at RT. The antibodies used included polyclonal rabbit anti-murine
JE/CCL2 (ProSci, Inc.) at 0.67 µg/ml, polyclonal rabbit anti-mouse MCP-5/CCL12
(Leinco Technologies, Inc.) at1 µg/ml, polyclonal goat anti-murine MCP-3/CCL7
(ProSci, Inc.) at 0.67 µg/ml, and the monoclonal mouse anti-FB29 gag antibody 34
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(generated at Rocky Mountain Laboratories, NIAID, NIH). After incubation, the wells
were washed twice as before with 100 µl of saponin. 50 µl dilutions of the appropriate
secondary antibodies were then added to each well and allowed to incubate at RT for 45
minutes. The secondary antibodies used include FITC conjugated goat anti-rabbit IgG
(Biomeda) at a concentration of 10 µg/ml, FITC conjugated goat anti-mouse IgG
(Zymed) at a concentration of 15 µg/ml, and FITC conjugated rabbit anti-goat IgG
(Zymed) at a concentration of 15 µg/ml. After incubation with the secondary antibody,
the cells were washed once as before with 100 µl of saponin, once with 1X PBS, and then
were diluted in 400 µl of 1X PBS, transferred to 5 ml round-bottom tubes (Falcon,
polystyrene, non-pyrogenic), covered with aluminum foil, and stored at 4º C until the
time of use.
Western Blot Analysis
Western Blot protein analysis was performed on DMEM growth media
supernatant from all of the C17.2 cell lines in order to confirm secretion of the
chemokines. Cells were passed as usual at a 1:10 ratio into individual wells of a 6-well
primaria culture plate containing 3 ml of DMEM growth media. After 48 hours the
media supernatant was collected and stored at -20º C until time of use. After thawing
samples, each was diluted 1:5 in 0.5% NP40/1X PBS. This mixture was then diluted 1:1
with Tricine Sample Buffer (Bio-Rad) containing β-mercaptoethanol as per product
guidelines. Next, sample mixtures were vortexed and boiled for 5 minutes at 100º C in
order to denature the native conformation of the proteins. 12.5 µl of each sample, as well
as 10 µl of Polypeptide Standard (Bio-Rad), were then added to individual wells in a 26well 16.5% Tris-Tricine pre-cast gel (Bio-Rad) immersed in 1X Tris/Tricine/SDS
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running buffer (Bio-Rad). The gel was run at 100 V for 100 minutes as per product
guidelines. Following this step the gel was allowed to equilibrate for 15 minutes in
chilled 1X Towbin buffer/20% methanol (transfer buffer). Fiber pads and filter paper
were soaked in chilled transfer buffer in preparation for setting up the transfer cassette. A
piece of immuno-blot PVDF membrane (Bio-Rad) was immersed in 100% methanol,
then transfer buffer, and carefully placed over the gel in the cassette. After being placed
on a stir plate and filled with chilled transfer buffer, an ice block was added to the
transfer apparatus and the assembled cassette was properly inserted. The transfer was
then run at 100 V for 60 minutes. The membrane was then removed and incubated on a
rocker for 1 hour at RT in 5% milk/1X TBS 0.05% Tween in order to block the blot for
protein/protein interactions. After blocking, the blot was placed in 20 ml of diluted
primary antibody and allowed to incubate overnight at 4ºC on a rocker. Primary
antibodies were diluted in 5% milk/1X TBS 0.05% Tween and included polyclonal rabbit
anti-mouse JE/CCL2 (Prosci, Inc.) at 0.2 µg/ml, polyclonal rabbit anti-mouse MCP-5
(Leinco Technologies, Inc.) at 0.2 µg/ml, and polyclonal goat-mouse MCP-3/CCL7
(Prosci, Inc.) at 0.2 µg/ml. Next, the blot wash washed three times on a rocker in 50 ml
of 1X TBS 0.05% Tween for 10 minutes at RT. The appropriate secondary antibody,
having been diluted in 50 ml of 5% milk/1X TBS 0.05% Tween, was then added to the
blot and allowed to incubate on a rocker for 1 hour at RT. Secondary antibodies used
included Horseradish Peroxidase (HRP) conjugated goat anti-rabbit IgG (Zymed) at a
concentration of 0.03 µg/ml, and HRP-conjugated rabbit anti-goat IgG (Zymed) at a
concentration of 0.03 µg/ml. Following secondary incubation, the blot was washed six
times on a rocker in 50 ml of 1X TBS 0.05% Tween for 10 minutes at RT in order to
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remove any excess antibody. To visualize the protein of interest, the blot was then
incubated for five minutes at RT in 10 ml of a 1:1 mixture of Femto West SuperSignal
Luminol Enhancer and Peroxidase buffer (Pierce). Excess detection buffer was allowed
to drip off, and the blot was then wrapped in cellophane, using a roller to carefully
remove all remaining enhancer/buffer. In a dark room the blot was placed in a cartridge
with a sheet of film (CL-X Posure Film, Pierce) for 30-60 seconds. The film was then
run through a processor and allowed to develop.
Mice
C17.2 Inoculation. The mouse strain used in this study was Inbred Rocky Mountain
White (IRW). Within 48 hours after the birth of each litter the NSCs were harvested by
the method hereafter described. Each of the different lines of C17.2 NSCs (untreated,
empty pSFF-transduced, and CCL2, CCL7, or CCL12-transduced) were grown up in 175
cm² flasks (Greiner Bio-one, Cellstar, non-pyrogenic, filter cap) with 35 ml of DMEM
growth media to approximately 95% confluency prior to inoculation. To collect the cells
the growth media was removed and 2 ml of 0.25% trypsin was used to wash the
monolayer. 10 ml of 0.25% trypsin was then added to detach the cells into solution. The
trypsin/cell mixture was then added to 15 ml of DMEM growth media in order to
deactivate the trypsin. This mixture was centrifuged for 5 minutes at 1500 RPM, and the
supernatant then discarded. The remaining pellet was then dislodged, mixed, and
centrifuged in 10 ml of 1X PBS in order to wash away any remaining growth media. The
supernatant was again discarded, and the cells brought up in 1 ml of 1X PBS and placed
on ice. In order to obtain the appropriate final concentration of 1.25 x 10^7 cells/ml the
cells were counted using a hemocytometer, and diluted in 1X PBS. The final suspension
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contained 0.001% Trypan Blue to assist in visualization during the inoculation. The
resulting suspension was then kept on ice until inoculation, however for no more than 1
hour. After proper preparation of the NSCs, the neonates, too young for gaseous
anesthetization, were placed in a deep hypothermic state in advance of inoculation.
Using a microsyringe, a total of 8 µl (10^5 cells at the prepared concentration) was
directly injected into the lateral cerebral ventricles (4µl in each side). The neonates were
allowed to come back to temperature, and were placed back with the dam. For each
experimental and control group there were 6 mice used per time-point.
Tissue Collection. Tissue samples were collected at 7, 14, and 21 days post-inoculation.
At the time of collection, all animals were placed under deep anesthesia by way of
IsoFlorane inhalation. Once anesthetized, the animals were exsanguinated through axial
incision, and then terminated by cervical displacement in accordance with approved
protocols. The entirety of the central nervous system tissue from the olfactory bulbs to
the brain stem was then carefully removed and sliced into two sagittal halves. One half
of the tissue was placed in 3.7% neutral buffered formalin for fixation and histological
analysis, and the other half was flash frozen in liquid nitrogen and stored at -80º C for
later molecular analysis.
Histology
In Situ Hybridization. All initial steps in this protocol were performed under RNAsefree conditions unless otherwise noted. Anti-sense DIG-labeled RNA probes were
generated prior to this study. In brief, whole RNA was isolated from the CNS of Fr98infected IRW mice. Following reverse-transcriptase PCR, the appropriate CCL
sequences were amplified and ligated into a T7 plasmid. Using a DIG RNA labeling kit
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the DNA plasmids were cut with the appropriate restriction enzyme to give a 5’
overhang. Restriction enzymes were then removed via phenol/chloroform extraction.
The cleaned and cut plasmid DNA was then incubated for 2 hours at 37º C with T7
polymerase in order to generate the anti-sense probe. The remaining DNA was then
removed by incubation with DNaseI incubation for 15 minutes at 37º C, and the reaction
stopped by the addition of 0.2M EDTA. The DIG-labeled probes were then purified
using Qiagen RNA cleanup columns, eluted using RNase-free water, and stored at -20º C
until further use. For the hybridization reaction, tissue samples were first baked
overnight at 56º C to help fix the paraffin-embedded tissue sections to the slides. Next,
the slides were placed in a glass Coplin jar and incubated overnight on a rocker in
Xylenes to de-wax the sections. The tissue was then rehydrated through successive
ethanol immersions (100%, 95%, and then 70%) for 5 minutes each on a rocker. The
sections were then incubated for 20 minutes at RT in 4% paraformaldehyde to fix the
tissue. After three rinses with 1X Tris-Buffered Saline (TBS) the slides were incubated
in 0.2 M HCl for 10 minutes to denature tissue proteins, and then again rinsed three times
with 1X TBS. In order to further denature the tissue proteins, the samples were incubated
for 20 minutes at 37º C each in 100 µl of 10µg/ml Proteinase K (Invitrogen)/1X TBS/0.2
M CaCl2. After again washing with 1X TBS as before, the samples were then incubated
in 1X TBS for 10 minutes at 4º C to deactivate any remaining Proteinase K activity. To
prepare the tissue for immersion in organic solvent, the sections underwent dehydration
through successive ethanols (70%, 95%, and 100%) on a rocker for 5 minutes each.
After incubation on a rocker in chloroform for 20 minutes at RT, the samples were
rehydrated in ethanol as before, then incubated in 2X SSC for 10 minutes. To prevent
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any random nucleic acid interactions between the specific RNA DIG-labeled probe and
the sample, each section was then incubated with 40 µl of Hybridization Buffer (2X SSC,
10% dextran sulfate, 0.01% sheared salmon sperm DNA, 0.02% SDS, 50% formamide),
covered with a parafilm coverslip, and placed at 56º C for 1 hour in a humidity chamber
containing 1X SSC/50% formamide. RNA probes were then diluted 1:100 from the stock
solution into Hybridization Buffer. Excess buffer was drained from the slides and 20 µl
of diluted probe was added to each tissue section. The slides were covered with a
Hybridization coverslip (Grace Bio-Labs), placed on a heat block at 95º C to help remove
any air bubbles, then incubated overnight at 56º C in the humidity chamber. The second
day of the in situ protocol was performed under non-RNAse-free conditions. The slides
were removed from the humidity chamber and placed in a plastic Coplin jar with 2X SSC
for 20 minutes where the Hybridization coverslips were allowed to float off. In order to
destroy any unbound and excess probe the slides were then incubated for 30 minutes at
RT with 100 µl of RNAse A (Roche) at 20µg/ml in 0.5 M NaCl/0.1 M Tris pH 8.0 per
section. Next the slides were rinsed with 2X SSC and then incubated twice for 30
minutes each in 50% formamide/1X SSC at 56º C. Following this, the slides were rinsed
with 1X SSC, and then allowed to incubate for 15 minutes at RT in 1X SSC. To block
non-specific interactions with the antibody the samples were incubated for 20 minutes at
RT in 1X Blocking Buffer (diluted in 1X Maleic Acid solution, Roche Biochemicals)
with a parafilm coverslip. To detect the DIG-labeled RNA probes the slides were
incubated with 100 µl per section of an alkaline phosphatase anti-DIG antibody (Roche
Biochemicals) diluted 1:500 in 1X Blocking Buffer for 1 hour at room temperature.
After allowing the antibody to bind to the labeled-probe, the slides were rinsed once in
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1X Blocking Buffer, and then three times in 1X TBS on a rocker for 15 minutes each.
After allowing the slides to incubate in detection buffer (0.1 M Tris-HCl pH 8.2) for 10
minutes at RT they were allowed to develop in a filtered Fast Red (Roche Biochemicals)
chromagen solution using a gasket coverslip for up to one week.
CD3 Immunohistochemistry. To detect the presence of CD3 positive lymphocytes in
the samples that were collected, the tissues were processed, embedded in paraffin, cut and
fixed to slides. In order to better adhere the sections to the slides they were all baked
overnight at 56º C. To de-wax the slides they were incubated in Xylenes twice for 15
minutes each at RT. The sections were then rehydrated through successive ethanol
incubations (100%, 95%, and 70% for 5 minutes each), then rinsed in 1X PBS. To
unmask the antigen of interest for detection the slides were placed in a glass Coplin jar
filled with Citrate Target Retrieval Solution (Dako), set in a bowl half-filled with water,
covered with cellophane, heated in a microwave for 20 minutes at 50% power, and then
again for 5 minutes at 50% power. After being allowed to cool for 20 minutes, the slides
were placed in a plastic Coplin jar and incubated in 1% hydrogen peroxide/1X PBS for
20 minutes in order to deactivate any indigenous peroxidases that might cause
background staining. In order to block any random protein/protein interactions involving
the primary antibody the slides were then incubated in a humidity chamber with 175 µl of
1% normal goat serum/1X PBS with a parafilm coverslip at 37º C for 30 minutes. The
polyclonal rabbit anti-human CD3 primary antibody (DakoCytomation) was diluted to a
working concentration of 6 µg/ml in 1% normal goat serum/1X PBS. After draining the
excess serum from the slides, 175 µl of the working antibody solution was added to each
slide, covered with a parafilm coverslip, and then incubated in a humidity chamber for 1
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hour at 37º C. Following incubation with the primary antibody the slides were washed
twice with 1X PBS on a rocker at RT. After the HRP-conjugated goat anti-rabbit IgG
(Zymed) secondary antibody was diluted to a working concentration of 5 µg/ml, 175 ul of
the solution was added to each slide, which were then covered with a parafilm coverslip
and incubated in a humidity chamber for 1 hour at 37º C. Slides were washed of excess
antibody in 1X PBS as before. Metal-enhanced DAB (Pierce) was diluted 1:10 in stable
peroxide substrate buffer (Pierce), vortexed, filtered through a 0.2 µM filter, and added to
each slide, via a gasket coverslip, to allow any positively bound antigen/HRP-antibody to
develop. Slides were then washed with ultra pure water, counterstained with
hematoxylin, and mounted with glass coverslips using Aquamount (Lerner Laboratories).
β-Galactosidase Immunohistochemistry. For purposes of in vivo detection of pSFF
C17.2 cells, immunohistochemistry was performed using an antibody specific for βgalactosidase, the lacZ reporter gene product. The protocol for detection of this antigen
begins in an identical fashion to the CD3 protocol up through the ethanol incubations. At
this point the slides were washed twice in 1X PBS/0.05% Tween for 5 minutes each. The
slides were then placed in a plastic TissueTek container filled with 250 ml citrate
retrieval buffer (4.5 ml of 0.1 M Citric Acid, 20.5 ml of 0.1 M NaCitrate dehydrate, 225
ml ultra pure water, brought to pH 6.0). The filled container holding the slides was then
placed in a BioCare Decloaking chamber filled with 500 ml of ultra pure water and run
for 20 minutes at a temperature setting of 120º C. After washing with 1X PBS-Tween
twice for 10 minutes each on a rocker the slides were blocked in 175 µl of 3% normal
goat serum/1X PBS-Tween with a parafilm coverslip in a humidity chamber for 30
minutes at RT. The rabbit anti-β-galactosidase primary antibody (Cappel) was diluted to

27

a working concentration of 30 µg/ml in 1% normal goat serum/1X PBS-Tween, added to
each slide in a 175 µl volume, covered with a parafilm coverslip, and allowed to incubate
for 30 minutes at RT in a humidity chamber. Slides were washed twice as before with
1X PBS-Tween and then incubated in 0.3% hydrogen peroxide/1X PBS-Tween to
inactivate any indigenous peroxidases. The secondary antibody used was the same as for
the CD3 protocol and was diluted to the same concentration (though in 1% normal goat
serum/1X PBS-Tween) and was applied to each slide with a 175 µl volume, covered with
a parafilm coverslip, and allowed to incubate for 30 minutes at RT in a humidity
chamber. Following two washes in 1X PBS-Tween as before, the slides were allowed to
develop in a 1:10 dilution of DAB/stable peroxide substrate buffer using gasket
coverslips, washed with ultra pure water, counterstained with hematoxylin and mounted
with a glass coverslip.
Post-In Situ Immunohistochemistry. In order to visualize the proximal effect of
chemokine over-production in the CNS on glial activation, immunohistochemistry was
performed on slides that had previously undergone the in situ protocol. The protocol for
these samples was identical to that used for CD3 detection, with the exception that all the
initial steps from Xylenes incubation through hydrogen peroxide incubation were
skipped. The protocol began with the blocking step (again using 1% normal goat
serum/1X PBS) and continued through development in DAB, counterstaining, and
mounting. The primary antibodies used were rabbit anti-mouse Iba1 (Wako) at a
concentration of 1 µg/ml for detection of microglia/macrophage activation and
infiltration, and rabbit anti-Glial Fibrillary Acidic Protein (GFAP) (DakoCytomation) at a
concentration of 2.4 µg/ml for detection of astrocyte activation. The HRP-conjugated

28

goat anti-rabbit IgG secondary antibody was used for both of the aforementioned
primaries at a concentration of 5 µg/ml.
RNA Preparation
Isolation from Cultured Cells. In order to establish the gene expression profiles of the
C17.2 NSC lines, whole RNA samples were isolated from each cell line for use in realtime PCR. Cells were maintained as previously described in 6-well primaria culture
plates with DMEM growth media. 48 hours after passing the cells at a 1:10 ratio two
confluent wells of each line were collected by trypsinization, added to 5 ml of fresh
growth media, and centrifuged at 1500 RPM for 5 minutes. The resulting pellets were
then washed with 5 ml of 1X PBS and again centrifuged. Once the pellets were collected
and washed, the RNA was then isolated using the materials and protocol provided with
the Zymo Mini RNA Isolation II kit. First, the pelleted cells were homogenized by
vortexing with 600 µl of ZR RNA Buffer. The resulting solution was transferred to a
Zymo-Spin III Column which was placed in a 2 ml collection tube and then centrifuged
at 14,000 RPM for 1 minute. This was followed by two successive washes and
centrifugation with 350 µl of RNA Wash Buffer. The column was then transferred to a
1.5 ml microcentrifuge tube, 50 µl of RNAse-free water was added, and the samples were
again centrifuged as before to elute the RNA from the column. The samples were then
placed at -80º C for storage until time of use.
Isolation from Primary Tissue. Whole RNA was isolated from the primary tissue
extracted from the mice in order to establish in vivo gene expression profiles via real-time
PCR analysis. For this process TRIzol Reagent (Invitrogen), and the accompanying
protocol, was employed. The tissue was removed from the -80º C freezer and kept in a
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bench-top cooler to prevent thawing until use. The first step was the homogenization of
the samples in 2 ml of TRIzol Reagent using a glass homogenizer. Each sample was then
separated into two tubes of 1 ml apiece to which 200 µl of chloroform was added and
shaken vigorously for 15 seconds. After allowing samples to incubate at RT for 3
minutes they were centrifuged at 10,000 RPM for 15 minutes at 4º C to achieve a phase
separation. The aqueous phase was then transferred to a new tube and 600 µl of
isopropanol was added to achieve precipitation of the RNA. Samples were allowed to
incubate at RT for at least 10 minutes, and then were centrifuged for 10 minutes at 10,000
RPM at 4º C to form a gel-like pellet of RNA. The supernatant was discarded, 1 ml of
70% ethanol was added, and the samples were vortexed in order to wash the pellet. After
centrifugation at 6000 RPM for 5 minutes at 4º C the ethanol supernatant was discarded,
and the pellet was allowed to dry for 10 minutes. To dissolve the RNA, 50 µl of RNAsefree water was added to each sample, which were then placed on a heat block at 55º C for
10 minutes, and then vortexed. All samples were then stored at -80º C until time of use.
DNAse Treatment. In order to prepare the isolated RNA for real-time PCR, all cellular
and primary tissue isolates were treated with DNAse to remove any residual genomic
DNA. First, the samples were removed from the freezer and thawed. For each sample of
primary RNA 5 µl was placed in a 1.5 ml microcentrifuge tube, while 10 µl volumes
were used for the cellular samples. 10 µl of DNAse buffer (Ambion) was then added to
each sample, followed by 15 µl of DNAse I (Ambion). RNAse-free water was then
added to each sample to achieve a final volume of 100 µl. After gently flicking the tubes
to mix the solutions, the samples were allowed to incubate for 30 minutes at 37º C.
Following incubation, the samples were purified using the Zymo RNA Clean-Up Kit
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materials and protocol. First, 400 µl of RNA-Binding Buffer was added to each sample
and mixed well via pipette action. Each sample mixture was then transferred to a ZymoSpin III Column, placed in a 2 ml collection tube, and centrifuged at 14,000 RPM for 1
minute. The waste in the collection tubes was discarded, the samples were washed twice
with 350 µl of Wash Buffer, and each time centrifuged for 1 minute at 14,000 RPM.
Columns containing the samples were then transferred to a fresh 1.5 ml microcentrifuge
tube. 50 µl of RNAse-free water was added to each column and centrifuged at 14,000
RPM for 1 minute to elute the purified RNA. DNAse-treated RNA samples were placed
at -80º C for storage until time of use.
Reverse Transcriptase PCR. Prior to use in real-time PCR analysis, DNAse-treated
RNA samples were first subjected to reverse-transcriptase PCR in order to generate
cDNA templates. Using the Bio-Rad iScript cDNA Synthesis kit a master mix was
generated which contained for each sample 10 µl RNAse-free water, 4 µl 5X iScript
Reaction Mix, and 1 µl iScript Reverse Transcriptase. 15 µl volumes of the master mix
were then aliquotted into 48 wells of a 96-well plate (Fisher Scientific, DNAse, RNAse,
and DNA-free)), to each of which was added 5 µl of each DNAse-treated RNA sample.
The plate was sealed with a pierceable foil sealing strip, vortexed, and centrifuged at
1500 RPM for 5 minutes. The plate was then run on a thermal cycler (MJ Research PTC
200) under the following conditions: 25º C for 5 minutes, 42º C for 30 minutes, 85º C for
5 minutes, and then 20º C indefinitely (to maintain the integrity of the cDNA product).
After the reaction was finished the plate was centrifuged as before, each sample was
diluted in 80 µl of RNAse-free water in individual 0.5 ml tubes, vortexed, centrifuged,
and then placed at -20º C for storage until time of use.
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Real-Time PCR Analysis
Primer Design. mRNA reference sequences for each of the genes being examined were
obtained at NCBI Gene. Primers were designed using the Primer3 website, and were
blasted for specificity using the NCBI nucleotide blast non-redundant database. Each
primer set was designed to be between 18 and 27 bases, with a G/C content between 20
and 80%, a Tm of 60º C, and with the desired amplicon being between 100 and 180 base
pairs. The sequences of the primers used for each gene include:
Actb-29f

CAGCTTCTTTGCAGCTCCTT

Actb-185r

CACGATGGAGGGGAATACAG

AMuLVenv-f

AGGCGCTTAACCTCACCAAT

AMuLVenv-r

GGAAGTGGCCGTACAGTTG

EnvMlvi4-1258f

GCATGTTCTGCATGTTGAGG

EnvMlvi4-1442r

CAAGAGTTGGGGTCAAGAGG

F480.2-1321f

ACAAGTGTCTCCCTCGTGCT

F480.2-1430r

AACATGGTGCTTTCCACAGTC

FB29gag2-613f

CCCGTGGCGGATTCTACT

FB29gag2-740r

TCGGAGAAAGAGGGGTTGTTA

Gapdh2-152f

AACGACCCCTTCATTGAC

Gapdh2-342r

TCCACGACATACTCAGCAC

Gfap-16f

CGTTTCTCCTTGTCTCGAATGAC

Gfap-112r

TCGCCCGTGTCTCCTTGA

MCP1.2-178f

CCCACTCACCTGCTGCTACT

MCP1.2-341r

TCTGGACCCATTCCTTCTTG
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MCP3-90f

TTCTGTGCCTGCTGCTCATA

MCP3-198r

TTGGGGATCTTTTGTTTCTTG

MCP5-58f

AGCTACCACCATCAGTCCTCA

MCP5-156r

CGGACGTGAATCTTCTGCTT

Plate Set-Up and PCR Reaction. To make plate set-up more efficient, cDNA samples
were first thawed, then dispensed 5 µl at a time into each well of 96-well plates (Fisher
Scientific, DNAse, RNAse, DNA-free), sealed with optical plate-sealing tape (Bio-Rad),
and stored at -20º C. At the time of use each plate was removed, thawed, centrifuged at
1500 RPM for 5 minutes, and then set in a 96-well plate bench-top cooling block while
the reaction mix was prepared. The master mix used for these reactions was prepared in
a UV sterilized PCR hood and contained the following reagent volumes per sample: 9 µl
RNAse-free water, 17.5 µl 2X iTaq SYBR Green Supermix with Rox (Bio-Rad), 1.75 µl
forward primer (at a 10µM concentration), and 1.75 µl reverse primer (at a 10µM
concentration). The master mix was vortexed and added in volumes of 30 µl to each
sample in the pre-prepared 96-well plate. After sealing the plate, it was vortexed and
then centrifuged at 1500 RPM for 5 minutes. The reaction mixture was then transferred
to a 384-well plate (Applied Biosystems) in triplicate, giving a final reaction volume of
10 µl per well. This plate was sealed with optical plate sealing tape (Applied
Biosystems), centrifuged as before, placed in the ABI 7900, and was subjected to the
following reaction conditions: 50º C for 2 minutes, 95º C for 3 minutes, then 40 cycles of
95º C for 15 seconds and 60º C for 1 minute, followed by a melting curve reaction of 95º
C for 15 seconds, 60º C for 15 seconds, and then 95º C for 15 seconds.
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Statistical Analysis
All statistical calculations were performed using Prism Graph Pad Software. 2way ANOVA with Bonferroni post-test analyses were calculated with significance set at
P<0.05.
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Results
C17.2 In Vitro Chemokine Expression
C17.2 Transgenic mRNA Expression. To generate chemokine C17.2 NSCs expressing
the proteins of interest, the cells were incubated in culture with pSFF vector virions
containing genes for CCL2, CCL7, or CCL12, or the empty vector as a control. Positive
transduction was confirmed by microscopic examination of cells fluorescently stained for
CCL or retroviral gag protein expression. Following confirmation of transgene
expression, six separate RNA isolates were collected for each of the C17.2 lines for
analysis via quantitative real-time PCR. This technique allows for a quantitative
comparison of cellular mRNA expression of the genes of interest relative to the
production of the housekeeping gene β-actin. All values shown in Figure 2 have been
calculated relative to the internal standard of β-actin mRNA expression within each cell
line, thus compensating for any differences in the quantities of viable RNA collected in
each isolate. Chemokine mRNA in each of the three CCL-producing lines was found to
be expressed at levels beyond that of the β-actin housekeeping gene. More revealing,
however, was the difference observed in CCL expression between each CCL-transduced
line and the next highest value observed. The CCL2 C17.2 line expressed CCL2 mRNA
at a relative level of 461-fold that of the next highest value observed, the CCL7 C17.2
line expressed CCL7 mRNA at a relative level of 1,112-fold that of the next highest
value, and the CCL12 C17.2 line expressed CCL12 at a relative level of 60-fold the next
highest value. Additionally, the CCL lines all expressed their respective chemokine
mRNA at levels significantly higher than the other C17.2 lines in comparison.
Interestingly, with regard to CCL2 and CCL7, all the lines expressed these genes at
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Figure 2. Chemokine and retroviral gag mRNA expression in transduced C17.2 neural
stem cell lines. Cells were harvested via trypsinization 48 hours after being plated. Total
RNA was purified from the cells and analyzed for the indicated chemokine and retroviral
mRNA by quantitative real-time PCR analysis. Variations within and between each
sample are normalized through presentation relative to the housekeeping gene β-actin.
Two-way ANOVA and Bonferroni post-test statistical analyses were performed for
results of each of the three CCL genes. Where indicated (*) statistical significance was
found with P<0.001 with respect to all other groups present in the comparison.
appreciably detectable levels, indicating that these genes may be innately expressed in the
C17.2 line. With respect to CCL12 however, while both the CCL2 and CCL7 lines
demonstrated detectable levels of expression, both the untreated C17.2 line and the pSFF
line showed essentially no expression of this gene. The CCL2 and CCL7 lines also
appear to be expressing CCL12 mRNA at a higher level than the basal levels of
expression seen with the other two CCLs. It is possible that the presence of CCL2 and/or
CCL7 in the cultures of those respective lines induced the production of CCL12 mRNA.
As high levels of these chemokines were not present in the pSFF or untreated C17.2
cultures, this could explain the absence of CCL12 production.
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As it is the only common transgene present between the transduced lines, levels of
retroviral gag mRNA expression were used as a molecular measure of relative levels of
gene transfer between the individual lines. The observed levels of expression for this
gene were similar between the CCL producing cell lines, and all the lines showed
significantly higher expression as compared with the undetectable level observed in the
untreated C17.2 cells. However, there was a disparity with regard to gag mRNA levels
detected in the empty pSFF vector control line, as the observed values were 9-fold lower,
and significant, compared to the next highest level of expression recorded. At the time
the initial experiment was conducted, this was the best rate of transduction we could
achieve with the empty vector. As a preliminary study for the feasibility of this model,
the low-level expressing pSFF-transduced cells were used for further experiments in this
project. Since the initial experiment we were able to transduce C17.2 cells with the
empty pSFF vector to produce a level of retroviral gag production comparable to the
other transduced lines.
*C17.2 Recombinant Retrovirus Contamination. During the course of this study it
became apparent that at about three months post-inoculation, mice that had been
inoculated with any one of the CCL2 C17.2, CCL7 C17.2, or CCL12 C17.2 lines were
becoming sick and dying. At necropsy it was determined that their death was the result
of multi-organ lymphosarcoma, a condition in mice that can be caused by recombinant
retrovirus infection (Starkey et al., 1998). Upon this discovery, quantitative real-time
PCR analysis was performed on RNA isolates from each of the C17.2 cell lines to test for
the presence of either ecotropic or amphotropic retrovirus env gene expression. Since the
retroviral particles used to transduce the cell lines were designed to be replication-
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Figure 3. Amphotropic and ecotropic retroviral env mRNA expression in C17.2 NSC
lines. Cells were harvested, total RNA was isolated, and mRNA expression analyzed by
quantitative real-time PCR as described in Figure 1. Variations within and between each
sample were normalized through presentation relative to the housekeeping gene β-actin.
Two-way ANOVA and Bonferroni post-test statistical analyses were performed for
results of each of the retroviral env genes. Where indicated (*) statistical significance
was found with P<0.001 and all samples being compared with the non-transduced C17.2
line.
deficient, in part due to the lack of an env gene, the presence in these cells of either of
these retroviral gene products would indicate that recombination had taken place, and
infectious, replicating virus was present. As Figure 3 indicates, every transduced C17.2
line used in this study was indeed contaminated with an infectious recombinant, and at
significant levels compared to the untreated line, in which there was no evidence of any
viral contamination. The pSFF C17.2 line contained evidence of both the ecotropic and
amphotropic recombinants, as did the CCL12 C17.2 line at slightly higher levels. Both
the CCL2 C17.2 and the CCL7 C17.2 lines were contaminated with only the ecotropic
recombinant. As a result of these findings, it would be difficult to use retroviral gag
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expression as an accurate point of comparison for gene transfer between the transduced
lines since the infectious recombinant retroviruses would also induce gag expression,
thereby confounding the observed results.
Flow Cytometry. Immunofluorescent staining and flow cytometry analysis was
employed to quantify the percentage of positively transduced cells within each
transduced population. The anti-CCL antibodies utilized produced mixed and
inconsistent results, and while each transduced cell line was clearly positive for the
appropriate protein, percentages varied between the lines from 40-80%, depending on
when the flow run was conducted (data not shown). Earlier results were more consistent,
and gave higher positive percentages for the CCL-producing cells, which would suggest
the possibility of recombinant retroviral influence on the population as the infection
proceeded with time.
Since a common antibody was needed to compare between the four transduced
lines, the anti-retroviral gag monoclonal antibody 34 was used to confirm positive
transduction rates. The data obtained from this antibody indicated similar levels of
transduction among the pSFF, CCL2, CCL7, and CCL12 C17.2 cell lines, with the
percent positive cells ranging from 85-95% (data not shown). However, the presence of
the replicating, infectious recombinant retrovirus within the cultured cells (as shown in
Figure 3) could confound the positive results seen for retroviral gag expression, and may
have influenced the overall make-up of the cultured population used in this analysis.
Thus, the percent of cells positively transduced with the intended retroviral insert cannot
be substantiated by the flow cytometry data obtained.

39

Cellular Secretion of CCL Proteins. As mRNA expression does not always correlate
with protein production, we needed to demonstrate that the individual C17.2 lines were
producing their respective CCLs, and confirm actual secretion of the chemokines. For
this purpose, Western Blot analysis was performed on supernatant collected from the
cultured C17.2 lines 48 hours after plating the cells. The same membrane blot was used
for each of the three antibody incubations so that the results could be accurately
compared. As shown in Figure 4, only culture supernatant from the appropriately
transduced cell lines demonstrated the presence of the individual CCL of interest, and no
errant or inherent CCL production was observed. All bands were observed at the
expected molecular weight of ~9 kDa. The dual bands seen in the CCL2 blot were
consistent with that protein’s reported tendency to persist in both the monomer and dimer
forms (Zhang and Rollins, 1995). As such, the larger of the two bands is observed at
approximately double the weight of the smaller monomer. A slight difference in intensity
was observed between the protein levels of the monomer forms of the individual CCLs.
This may be due to the necessary use of different secondary antibodies, the stripping
process, or possibly the avidity or sensitivity of the different polyclonal antibodies.
Additionally, the somewhat greater intensity of the CCL12 band may correspond to the
slightly higher levels of mRNA expression observed in the quantitative real-time PCR
results.
In Vivo Chemokine Expression
Chemokine mRNA Expression in the CNS. So that a proper comparison could be
made between the experimental effects of the chemokine expressing C17.2 lines in vivo,
and also to generally describe the in vivo characteristics of the system, the relative levels
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Figure 4. Western Blot analysis of C17.2 neural stem cell culture supernatants. Growth
media from each of the four transduced lines, and the untreated line, was collected for
protein analysis following 48 hours of incubation. The samples were subjected to SDSPAGE, blotted on a PVDF membrane, and incubated with polyclonal antibodies to each
of CCL2 (A), CCL7 (B), and CCL12 (C) to confirm cellular secretion of the appropriate
chemokine.
of transgenic chemokine expression in the CNS had to be established. For this purpose,
CNS samples were collected at 7, 14, and 21 days following inoculation with the
transduced cells. Brain tissue was divided into two sections at the mid-sagittal region,
with half of each brain processed for RNA. The whole RNA isolated from these samples
was then prepared for quantitative real-time PCR analysis as described in the methods
section. CCL2 mRNA expression was significantly higher for the CCL2 C17.2-treated
mice compared with the other groups for all time points tested, and increased with each
interval possibly due to increasing migration of the cells into the brain tissue, or division
of the inoculated cells (Figure 5A). CCL7 mRNA expression in the CCL C17.2-treated
mice showed a similar pattern of increased chemokine expression with time (Figure 5B).
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Figure 5. Chemokine mRNA expression in the central nervous system of neonatal
Inbred Rocky Mountain White mice treated with one of four transduced C17.2 neural
stem cell lines. All mice were intracranially inoculated through the lateral cerebral
ventricles with 10^5 cells within 48 hours after birth. Total RNA was isolated from
sagittal sections of brain samples collected at the indicated times post-inoculation.
Relative mRNA expression for each of CCL2 (A), CCL7 (B), and CCL12 (C) was
analyzed by quantitative real-time PCR. Variation within and between samples was
normalized by presentation relative to the housekeeping gene β-actin. 5D represents
relative CCL mRNA expression levels after adjusting for expression in the pSFF C17.2
treatment group. Two-way ANOVA and Bonferroni post-test statistical analyses were
performed on all data shown, and where indicated (*) statistical significance was seen
with P<0.05 with respect to all other experimental groups present in the analysis.
However, the CCL7 levels observed at the initial time point of 7 days p.i. showed little
difference between the four groups. This suggests that CCL7-positive cells may migrate
more slowly than the other cell types into the brain tissue. The CCL12 C17.2-treated
mice also showed consistently higher CCL12 mRNA expression compared to the other
groups (Figure 5C).
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To compare relative increases in gene expression in vivo, the ratio of increased
expression relative to the pSFF control group was calculated for each CCL. The adjusted
comparison of CCL gene expression in the three CCL C17.2- treated groups across the
observed time points also demonstrated that regardless of whatever effect the
contaminating retroviruses may have had, the system reliably expressed the appropriate
chemokine gene at comparable levels in vivo (Figure 5D). With the exception of CCL7
at 21 days p.i., the three chemokine genes were expressed at statistically similar levels at
all time points. This observation allows for suitable comparison of the effects of the three
chemokines in vivo, with at the very least being able to use each chemokine as a control
for the other.
In Vivo Localization of Chemokine-Producing C17.2 Cell Lines. In order to further
define the in vivo characteristics of the system, we sought to delineate the migratory
distribution of the transduced cells in the CNS of the treated mice at the three time points
studied. To this end two histological techniques were employed with varying degrees of
success. First, in situ hybridization was performed on sagittal sections of all the
treatment groups for each of the three chemokines, CCL2, CCL7, and CCL12 (Figure 6).
Sections from each of the three chemokine-expressing groups were then scored for the
presence of CCL-positive cells in each of the olfactory bulb, cortex/hippocampus,
thalamus/midbrain, colliculus, cerebellum, brain stem, and meningial regions of the CNS
(Table 1). Due to variations in sensitivity to detection of gene expression between
samples, and the analysis of sagittal sections with varying depth from the mid-sagittal
region, these results were used only to identify general trends in cell migration, rather
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Table 1. Localized distribution of transduced C17.2 neural stem cells in the central
nervous system of treated neonatal Inbred Rocky Mountain White mice. All mice were
intracranially inoculated through the lateral cerebral ventricles with 10^5 cells within 48
hours after birth. Whole brain samples were removed at the indicated times postinoculation, sagittally sectioned, and fixed in 3.7% neutral buffered formalin. In situ
hybridization analysis for mRNA of each of the three CCLs was conducted on the six
mice used in each group. The data presented represents scoring of each of the seven
general areas of the brain for the presence of positively stained cells as seen following in
situ hybridization. The presence of no positively stained cells is represented as 0, 1-10
cells is represented as *, 11-50 cells as **, and 51+ cells as ***.

Table 1 Continued
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than quantitative assessment of cell location. All treatment groups demonstrated similar
patterns of in situ-positive cell presence in the regions examined. At day 7 p.i. the cells
were most consistently observed in the meninges. By day 14 p.i. greater numbers of
chemokine-producing cells were visible in the major regions of the brain, indicating
further penetration of the cells into the tissue. Lastly, at day 21 p.i. the vast majority of
the transduced cells were found in the interior regions of the brain rather than in the
meninges. The most consistent region to which the greatest number of cells eventually
trafficked was the thalamus/midbrain region, which is also consistent with this area’s
proximity to the lateral ventricles.
Since the pSFF C17.2 control line obviously could not be detected via in situ
hybridization for CCL production, these sections were examined by
immunohistochemical analysis for the presence of β-galactosidase, the marker protein
produced by the lacZ gene included in the C17.2 NSC line. Again, staining was
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Figure 6. Transduced C17.2 neural stem cells in the CNS of inoculated mice. Panels 6A
through 6F show positive staining of chemokine-producing transduced C17.2 NSCs by in
situ hybridization. Meningial localization of CCL12 C17.2 cells at day 7 p.i. (6A, 20X
magnification). CCL7 C17.2 cells in the olfactory bulb at day 21 p.i. (6B (4X
magnification) and 6D (10X magnification)). CCL12 C17.2 cells in the brain stem at day
14 p.i. (6C, 10X magnification). CCL2 C17.2 cells in the thalamus at day 21 p.i. (6E, 4X
magnification). CCL12 C17.2 cells in the thalamus at day 14 p.i. (6F, 40X
magnification). Panels 6G through 6I show β-galactosidase-positive staining by
immunohistochemistry. pSFF C17.2 cells in the olfactory bulb at day 21 p.i. (6G, 20X
magnification). pSFF C17.2 cells in the thalamus at day 14 p.i. (6H (10X magnification)
and 6I (40X magnification)).
inconsistent, but for those sections that were positive it was clear that the cells tracked to
similar regions of the CNS as the chemokine-producing cells (Figure 6G-I). As increased
mRNA expression of the CCL of interest was detected in all tissue samples (Figure 5),
the lack of C17.2 detection by in situ hybridization or immunohistochemistry for some
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Figure 7. In situ hybridization for CCL expression in the thalamus/mid-brain regions of
inoculated mice. 7A, 7D, and 7G are samples collected from CCL2 C17.2-inoculated
mice. 7B, 7E, and 7H are samples collected from CCL7 C17.2-inoculated mice. 7C, 7F,
and 7I are samples collected from CCL12 C17.2-inoculated mice. Samples in 7A
through 7C were collected at day 21 p.i. and stained using probes specific for CCL2.
Samples in 7D through 7F were collected at day 21 p.i. and stained using probes specific
for CCL7. Samples in 7G through 7I were collected at day 14 p.i. and stained using
probes specific for CCL12. Positively stained sections were seen in CCL C17.2inoculated mice only when subjected to staining with the appropriately corresponding in
situ probe. All pictures were taken at a lens magnification of 4X.
tissue samples appears to be the result of variations in tissue handling, processing, or
slide preparation, rather than an actual deficit of chemokine-producing cells.
Additionally, as can be seen in Figure 7, the CCL mRNA detected by the in situ
hybridization was specific to the appropriate experimental group. Each treatment group
was stained using all three of the CCL-specific probes, but no positive staining was
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observed where it was not expected, showing that the CCL over-expression was due to
the specific transduced cells that were inoculated, and not to a general immune reaction
to the presence of the cells.
Glial Activation and Inflammatory Infiltration
CNS mRNA Expression of Molecular Markers for Microglia/Macrophage and
Astrocyte Activation and Infiltration. CCL2, CCL7, and CCL12 have all been
associated with neurological diseases of which glial activation is a common characteristic
(Conant et al., 1998; McManus et al., 1998; Simpson et al., 1998; Van, V et al., 1999; Xia
et al., 1998). Additionally, these three chemokines have been well-characterized as being
chemotactic for monocytic cells (Fuentes et al., 1995; Gonzalo et al., 1998; Gunn et al.,
1997; Sarafi et al., 1997; Sozzani et al., 1994; Sozzani et al., 1995). As such, one of the
purposes of this study, beyond characterizing the system, was to examine the effects of
individual CCL over-expression on CNS glial activation and/or macrophage infiltration.
To this end, molecular analysis was performed on RNA isolates from each group and
each time point by quantitative real-time PCR. mRNA expression of the astrocyte
activation marker Glial Fibrillary Acidic Protein (GFAP) was used as a means of
determining relative astrocyte activation, while mRNA expression of the
microglia/macrophage activation marker F4/80 was used to measure relative microglia
activation and macrophage recruitment. F4/80 mRNA expression remained at a
consistent level across all three time points for all treatment groups, with the exception of
the CCL7 C17.2 group (Figure 8A). Here there was a decrease in expression to a
significant level at both days 14 and 21 p.i. relative to the pSFF C17.2 control. GFAP
mRNA expression analysis gave similar results with the CCL7 C17.2 group showing a
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Figure 8. mRNA expression of glial activation markers in the central nervous system of
Inbred Rocky Mountain White mice treated with one of four transduced C17.2 neural
stem cell lines. All mice were treated, and RNA isolated, as previously described in
Figure 5. mRNA expression for the macrophage/microglia activation marker F4/80 (8A),
and the astrocyte activation marker GFAP (8B) were analyzed by quantitative real-time
PCR. Variation within and between samples was normalized by presentation relative to
the housekeeping gene β-actin. Two-way ANOVA and Bonferroni post-test statistical
analyses were performed on all data shown, and where indicated (*) statistical
significance was seen with P<0.05 with respect to values observed for the pSFF C17.2
control group.
slight, but significant decrease at day 14 p.i, and both the CCL2 C17.2 and CCL12 C17.2
groups showing a slight decrease in expression relative to the pSFF C17.2 control groups
at day 21 p.i. (Figure 8B). Unexpectedly, the group inoculated with untreated C17.2 cells
showed similar levels of mRNA expression of both glial activation markers when
compared to all other treatment groups, suggesting that the presence of recombinant
viruses played no part in inducing the expression of these genes. Additionally, the
relatively lower basal levels of expression of both molecular markers seen in the
untreated group of mice (not shown) suggests that levels observed in the treatment
groups, controls included, may be due to a response to the invasive nature of the
inoculation process, and not to the presence of the infectious recombinants or the effects
of chemokine over-expression.
Immunohistochemical Analysis of Glial Activation and Inflammatory Infiltration
In order to complement the molecular data obtained for glial activation, and to determine
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Figure 9. Glial activation in the thalamus/mid-brain region of CCL C17.2-treated mice.
9A is from day 21 p.i. of a mouse inoculated with CCL2 C17.2-expressing cells. The
section was dual-stained for CCL2 mRNA via in situ hybridization (red staining), and
reactive astrocytes via immunohistochemistry for GFAP expression (brown staining). 9B
is from day 14 p.i. of a mouse inoculated with CCL12 C17.2-expressing cells. The
section was dual-stained for CCL12 mRNA via in situ hybridization (red staining), and
reactive microglia/macrophages via immunohistochemistry for Iba1 expression (brown
staining). Both pictures were taken at a lens magnification of 40X.
proximity of activated glial cells to the CCL-producing stem cells, immunohistochemical
analysis was performed on fixed sagittal sections taken from the treated mice. AntiGFAP antibodies were used to assess astrocyte activation, and anti-Iba1 antibodies
wereused to detect microglia/macrophage activation and recruitment. Our histological
observations supported the molecular results in that there was no visually noticeable
difference in the overall number and distribution of activated glial cells between the CCL
and pSFF or untreated C17.2 treatment groups (not shown). Additionally, as
demonstrated in Figure 9, there was no visible evidence of reactive glia staining positive
for any of the three CCLs being examined, showing that the significant up-regulation of
each of the CCLs was not due to glial production.
Immunohistochemical analysis using anti-CD3 antibodies was also performed to
determine the extent, if any, of lymphocytic infiltration in the CNS due to the over-
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expression of the three CCL chemokines. No visually significant CD3-positive
lymphocyte infiltration was present in any of the treatment groups (not shown).
Gross Pathology
In order to fully assess any histopathological effects of the over-expression of
CCL2, CCL7, or CCL12 in the CNS, H&E stained tissue sections were examined for
each sample. Interestingly, the presence of spongiform degeneration was observed in the
thalamus/mid-brain section of a large number of CNS samples from the CCL12 C17.2
treatment group (Figure 10). In a majority of these samples the pathology was evident by
day 14 p.i., and was also present in the day 21 samples of the same group. The presence
of both the amphotropic and ecotropic recombinant viruses in the CCL12 C17.2 cells
confounds these observations, especially given prior evidence that these viruses are
associated with such histopathology (Munk et al., 1997). However, all other groups
inoculated with transduced cell lines were also contaminated with recombinant virus,
including the pSFF C17.2 group with both varieties, and this effect was not seen with any
consistency.

Consequently, these results suggest the possible involvement of CCL12 in

spongiform degeneration, if not on its own, then at least in the presence of a retrovirus
infection.
Fr54 Retrovirus Infection Concomitant with CCL C17.2 Inoculation
It is currently unclear what the precise roles of CCL2, CCL7, or CCL12 are, if
any, in the development of neurological disease. It is likely that CCL over-expression
alone is not directly responsible for clinical disease during retrovirus infection, and the
possibility remains that some aspect of the viral replication cycle is necessary in
conjunction with immune factor expression to induce disease. As such, we employed the
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Figure 10. Spongiform degeneration in the CNS of mice inoculated with CCL12 C17.2
neural stem cells. The thalamus/mid-brain region of H&E stained tissue sections at day
14 p.i. (10A (20X magnification)) and day 21 p.i. (10B (20X magnification)). 10C (10X
magnification) shows the colliculus at day 21 p.i. in a tissue section dual stained for
CCL12 mRNA by in situ hybridization (red staining), and GFAP by
immunohistochemistry (brown staining).
use of the non-neurovirulent retrovirus Fr54 infection in conjunction with inoculation
with the CCL-expressing C17.2 cells to observe for the development of signs of clinical
neurological disease. Fr54 viral stocks were generated in culture and each treatment
group was intraperitoneally infected with 100 µl of virus stock, while simultaneaously
being inoculated with the CCL C17.2 cells as described previously. Each group was
observed for 21 days post-infection with no signs of disease ever developing.
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Discussion
The first objective of the present study was to establish the in vivo CNS
expression of CCL chemokines via retroviral-transduced C17.2 neural stem cells. This
was accomplished using pSFF vector virions containing the individual CCL genes that
were generated in ψ2/PA317 retroviral packaging cell co-cultures. Real-time PCR
analysis of RNA isolates from each cell line revealed some variation in the levels of
expression of CCL mRNA among the respective chemokine-producing cell lines;
however the results overall revealed analogous patterns of expression when compared to
the other lines tested for each specific CCL.
Retroviral gag expression in the transduced cell lines was intended to be used as a
relative measure of gene transfer at both mRNA and protein levels. However,
recombinant retrovirus contamination in the transduced cultures invalidated these results,
as this gene could also be transferred by the recombinants. As such, it became evident
that the later inconsistencies in the percentages of CCL-positive cells observed in the
flow cytometry data could have been due, in part, to disruptive selection in the transduced
populations caused by these viruses. In all, the presence of the recombinants prevented
an accurate measure of the rate of transduction.
While the in vitro data obtained was partially tainted by the presence of
contaminating retroviruses, the potential effects of the recombinant contamination were
not evident in the in vivo data that was generated by this study. CCL2, CCL7, and
CCL12 mRNA were all expressed at significant and consistently higher levels in their
respective treatment groups as compared to the controls. Additionally, CCL mRNA
expression, when adjusted for basal levels, was found to be quite consistent for each of
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the three CCL C17.2-treated groups. These observations give support to the idea that this
system provides a viable means to study different CNS chemokines being produced at
consistently high levels in vivo, which would allow for reliable cross-comparison of any
effects seen.
One of the unknowns that had to be addressed with this system was the migratory
patterns of the chemokine-expressing C17.2 cells to different regions of the brain, and the
potential effects on the distribution of chemokine production. In the current study, as
seen through in situ hybridization analysis, there was clear evidence of wide
dissemination of the desired gene product. While the inconsistencies in positive staining
between samples prevented any quantitative assessment of C17.2 migration, this may
have resulted from the use of sections with different spatial relationships from the midsagittal point, or variations in tissue processing. Additionally, the CCL mRNA
expression observed in all samples as determined by real-time PCR analysis verifies the
presence of the CCL-producing cells, and supports tissue processing as a cause for the
inconsistencies seen. Nevertheless, chemokine-expressing cells for all three CCL groups
were present in every major region of the brain, both interior and exterior. Furthermore,
no difference was observed in the migration pattern of the pSFF C17.2 control cells in
comparison with the CCL-producing C17.2 cells. This data indicates that there was most
likely no auto-stimulatory homing effect of the chemokines on the C17.2 cells. Though
in vitro studies demonstrated that CCL2 could induce the migration of neural progenitor
cells, the expression of the chemokines by the C17.2 cells themselves may not generate
the necessary directional gradient, or the constant exposure in culture could have desensitized the transduced cells to the chemotactic effects of the chemokines (Widera et
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al., 2004). Nonetheless, the migratory nature of the transduced C17.2 system could
provide a more accurate representation of the spatial distribution of activated, chemokineproducing glia seen with neurological conditions, rather than asserting a more
concentrated effect such as with direct injection of the chemokine (Perrin et al., 2005).
Since one of the most consistently reported functions of CCL2, CCL7, and
CCL12 is the ability to chemoattract cells of monocytic lineage, we expected to see an
increase in the expression of molecular markers of activation for these cells in
conjunction with the over-expression of the CCL chemokines in vivo (Fuentes et al.,
1995; Gonzalo et al., 1998; Gunn et al., 1997; Sarafi et al., 1997; Sozzani et al., 1994;
Sozzani et al., 1995). Additionally, as astrocyte activation often correlates with the
presence of increased production of pro-inflammatory chemokines during the course of
disease, we also investigated the potential effect of the CCL over-expression on the
population of these cells in the CNS (Persidsky et al., 1999; Peterson et al., 2004; Van, V
et al., 1999). Somewhat surprisingly, our results gave no evidence of significant glial
activation or monocytic infiltration as a result of CCL over-expression, either by mRNA
analysis, or by histological examination. These observations reveal two important facts.
First, they suggest that even though there was the presence of recombinant retroviruses,
this infection had no obvious influence on the in vivo effects of the system. This is
evident by the similar levels of both GFAP and F4/80 mRNA expression seen in all
groups that were inoculated with C17.2 cells, including the untreated C17.2 cell line
which possessed no detected contaminating infection. Considering the apparent absence
of recombinant influence in vivo on glial activation, this data can be further interpreted to
say that the over-expression of CCL2, CCL7, or CCL12 alone did not have any
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significant impact on glial activation or monocytic infiltration in the CNS. This is in
agreement with previous CCL2 transgenic studies that showed the chemokine had no
major effects until the CNS was stimulated with a pathogenic medium, suggesting more
of an immune priming function (Huang et al., 2002). This concept can also be extended
for both CCL7 and CCL12 now as there previously was no direct study of the effects of
over-expression of these chemokines in the CNS. When considering the possible priming
effect though, it is interesting that even in the presence of the infectious recombinants
there was no observed immune activation. This suggests the possibility that these
chemokines lack the ability to assert a detectable unilateral immune response, and that
they potentially require the presence of some other soluble immune factor, or possibly a
more pathogenic medium, to assert their full influence.
Another interesting, and initially unexpected effect observed, was the consistent
presence of spongiform degeneration in the thalamus/mid-brain region of the CCL12
C17.2-treated mice. While it has been reported that the presence of amphotropic
recombinant retroviruses have been associated with this pathological phenomenon, the
absence of this effect in the other treatment groups where recombinant virus was also
present suggests the possible involvement of CCL12 in initiation or exacerbation of
spongiform degeneration (Munk et al., 1997). Lending support to this analysis was the
close proximity of the spongiform lesions to the main region of C17.2 migration. Since
the spongiform mechanism is not fully understood, this data, while preliminary, presents
the possibility of CCL12 involvement, potentially in jump-starting some signaling
cascade that leads to cellular vacuolization. As this was an incidental finding, and not the
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focus of this study, further investigation will be needed to establish any kind of
conclusive role for CCL12 in spongiform degeneration.
While there are clearly improvements to be made, and obstacles to overcome in
the continued development of this system, this study represents a positive first step in
providing a reliable model for examining individual chemokine over-expression in the
CNS. The most glaring concern is the confounding presence of two types of recombinant
retroviruses. Upon further investigation into the matter, it has become evident that
recombinant production is an inherent characteristic of the ψ2/PA317 retroviral
packaging cell co-culture method for generating virions for transduction. It is a
possibility that the use of this co-culture system in conjunction with the pSFF vector
specifically increased the likelihood of recombination. Since pSFF still maintains partial
envelope sequences, there could be regions of homology that exist within the vector with
respect to the envelope sequences found in the packaging cells that would promote
recombination. This phenomenon could also be a result of potentially homologous
regions existing in pSFF with regard to the altered ψ sequences found in the packaging
cell lines. Additionally, based on the evidence provided via the real-time PCR detection
of the ecotropic and amphotropic envelope sequences in vitro we can not definitively
conclude that there was a true replication competent recombinant virus present in vivo, as
it remains a possibility that only the envelope sequences were transferred to the pSFF
virions, and not the ability to actually replicate. We are currently addressing these issues
by examining the feasibility of a variety of other packaging cell lines in conjunction with
the pSFF retroviral vector. These new cell lines maintain the retroviral envelope and
packaging sequences on separate plasmids, and therefore further reduce the potential for
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recombination. Additionally, since we have now developed effective means of detecting
the presence of, at the very least, recombinant envelope expression, regular testing of
transduced C17.2 cultures for the presence of contaminating recombinant virus will help
reduce the possibility of confounding variables in the future.
While the reduced capacity for recombination would obviously allow for a more
complete assessment of the validity of this system, there are additional factors that need
to be considered when making further adjustments. For one, an accurate quantification of
both in vitro and in vivo CCL protein production should be undertaken via ELISA or
possibly Bio-Plex assay in order to complement the mRNA expression analysis, and help
to further define the function of the system. Additionally, the effects of the actual
inoculation procedure need to be taken into account with regard to any effects observed.
An additional control group could potentially be added to allow consideration of any
immune response that might result from the needle puncture required for delivery of the
CCL-expressing cells. A dual-staining technique making use of the C17.2 expression of
β-galactosidase must also be optimized that would give definitive evidence, as opposed to
the indirect evidence provided in this study, that the CCL-expressing cells observed in
vivo are truly the transduced C17.2 cells that were used in the inoculation.
Once the missing links in this system have been dealt with in a satisfactory
manner, however, there are a number of potential applications beyond what was
examined here. In its usefulness as a model for accurate examination of the isolated in
vivo effects of individual CNS chemokine over-expression, other factors could be
examined. A more in-depth analysis of the effects on resident glia and neuronal function
should be attempted, possibly focusing on more localized effects in the areas directly
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surrounding the chemokine-producing cells. Additionally, in continuing with the idea
that these factors act as primers for the immune response, there could be a subsequent
pathogenic or toxic stimulation, perhaps pertussis toxin, LPS, or a more pathogenic virus,
in order to assess either the exaggerated immune response that may follow, or potentially
the protective effects that have been proposed for these chemokines. This system should
provide the opportunity for more studies that will provide a reasonable examination of
immune factor over-expression in the CNS in a manner more consistent with what is seen
during the course of naturally occurring neurological conditions.
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